Get the Stockscreener App
68.31
0.29%
0.20
After Hours:
68.51
0.20
+0.29%
Ptc Therapeutics Inc stock is traded at $68.31, with a volume of 816.04K.
It is up +0.29% in the last 24 hours and up +11.31% over the past month.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.
See More
Previous Close:
$68.11
Open:
$67.86
24h Volume:
816.04K
Relative Volume:
0.66
Market Cap:
$5.43B
Revenue:
$900.66M
Net Income/Loss:
$-453.20M
P/E Ratio:
-11.50
EPS:
-5.94
Net Cash Flow:
$-274.19M
1W Performance:
+2.88%
1M Performance:
+11.31%
6M Performance:
+37.06%
1Y Performance:
+71.12%
1-Day Range:
$67.56
$69.28
1-Week Range:
$66.00
$69.88
52-Week Range:
$35.95
$69.88
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Name
Ptc Therapeutics Inc
Sector
Industry
Phone
(908) 222-7000
Address
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Compare PTCT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
68.31 | 5.41B | 900.66M | -453.20M | -274.19M | -5.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Jun-17-25 | Initiated | Truist | Buy |
| May-09-25 | Upgrade | BofA Securities | Neutral → Buy |
| May-07-25 | Upgrade | Citigroup | Sell → Neutral |
| Mar-11-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Mar-07-25 | Initiated | Scotiabank | Sector Perform |
| Dec-13-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-03-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Sep-04-24 | Initiated | Robert W. Baird | Outperform |
| Aug-26-24 | Resumed | UBS | Buy |
| May-20-24 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Dec-19-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Oct-30-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-27-23 | Downgrade | Citigroup | Neutral → Sell |
| Oct-06-23 | Downgrade | Truist | Buy → Hold |
| Sep-18-23 | Downgrade | Citigroup | Buy → Neutral |
| Sep-15-23 | Downgrade | Raymond James | Outperform → Underperform |
| Mar-17-23 | Initiated | SVB Securities | Market Perform |
| Dec-14-22 | Initiated | Goldman | Sell |
| Sep-12-22 | Initiated | Jefferies | Buy |
| Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Apr-04-22 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-18-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Apr-26-21 | Resumed | Credit Suisse | Neutral |
| Mar-29-21 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Feb-12-21 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-05-21 | Upgrade | Citigroup | Neutral → Buy |
| Nov-30-20 | Downgrade | RBC Capital Mkts | Sector Perform → Underperform |
| Oct-30-20 | Downgrade | Citigroup | Buy → Neutral |
| Oct-28-20 | Initiated | UBS | Neutral |
| Oct-07-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Apr-09-20 | Upgrade | Citigroup | Neutral → Buy |
| Feb-20-20 | Downgrade | Citigroup | Buy → Neutral |
| Feb-20-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-12-19 | Initiated | SunTrust | Buy |
| May-13-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Apr-11-19 | Initiated | Bernstein | Outperform |
| Oct-03-18 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-19-18 | Initiated | Credit Suisse | Outperform |
| Jun-18-18 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-04-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-29-18 | Resumed | RBC Capital Mkts | Sector Perform |
| Nov-16-17 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-26-17 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Oct-09-17 | Downgrade | JP Morgan | Neutral → Underweight |
View All
Ptc Therapeutics Inc Stock (PTCT) Latest News
Is PTC Therapeutics Inc. stock a top pick in earnings season2025 Performance Recap & Advanced Swing Trade Entry Plans - newser.com
Brighton Jones LLC Invests $226,000 in PTC Therapeutics, Inc. $PTCT - MarketBeat
Can PTC Therapeutics Inc. stock reach $100 price targetWeekly Market Outlook & Daily Volume Surge Trade Alerts - newser.com
Published on: 2025-11-02 01:56:33 - newser.com
Is PTC Therapeutics Inc. (BH3) stock safe for risk averse investorsJuly 2025 Snapshot & Fast Moving Stock Watchlists - newser.com
How to read the order book for PTC Therapeutics Inc.July 2025 EndofMonth & Growth Oriented Trading Recommendations - newser.com
PTC Therapeutics submits NDA for Friedreich ataxia treatment vatiquinone - MSN
PTC Therapeutics (NASDAQ:PTCT) Director Sells $1,088,787.00 in Stock - MarketBeat
Why PTC Therapeutics Inc. (BH3) stock is trending on social media2025 Institutional Moves & Weekly Chart Analysis and Guides - newser.com
AlphaQuest LLC Raises Stake in PTC Therapeutics, Inc. $PTCT - MarketBeat
Published on: 2025-11-01 00:56:06 - newser.com
Insider Sell: Emma Reeve Sells 15,666 Shares of PTC Therapeutics Inc (PTCT) - GuruFocus
PTC Therapeutics Inc expected to post a loss of $1.37 a shareEarnings Preview - TradingView
Reeve Emma, director at Ptc Therapeutics, sells $1.08 million in shares - Investing.com Australia
Reeve Emma, director at Ptc Therapeutics, sells $1.08 million in shares By Investing.com - Investing.com South Africa
PTC Therapeutics (NASDAQ:PTCT) Hits New 12-Month HighWhat's Next? - MarketBeat
Ptc Therapeutics stock hits 52-week high at 69.53 USD By Investing.com - Investing.com Australia
How Investors May Respond To PTC Therapeutics (PTCT) Analysts' Optimism on Sephience Launch Momentum - Sahm
PTC Therapeutics to Participate at Upcoming Investor Conferences - Barchart.com
How PTC Therapeutics Inc. stock compares to growth peersDividend Hike & Safe Capital Growth Plans - newser.com
PTC Therapeutics Inc. stock prediction for this weekWeekly Trend Recap & Low Risk Entry Point Guides - newser.com
Will PTC Therapeutics Inc. (BH3) stock attract long term capital inflowsJuly 2025 Sector Moves & Community Consensus Trade Alerts - newser.com
Detecting support and resistance levels for PTC Therapeutics Inc.Rate Hike & Safe Entry Point Alerts - newser.com
PTC Therapeutics (NASDAQ:PTCT) NASDAQ Composite Leads Biotech - Kalkine Media
How to forecast PTC Therapeutics Inc. trends using time seriesWall Street Watch & Technical Entry and Exit Alerts - newser.com
Ptc Therapeutics stock hits 52-week high at 69.53 USD - Investing.com
How Recent Developments Are Shaping the PTC Therapeutics Investment Story - Yahoo Finance
PTC Therapeutics (PTCT) to Release Earnings on Tuesday - MarketBeat
Published on: 2025-10-29 06:46:31 - newser.com
PTC Therapeutics, Inc. $PTCT Shares Sold by Allianz Asset Management GmbH - MarketBeat
Sector ETF performance correlation with PTC Therapeutics Inc.July 2025 Patterns & Weekly High Momentum Picks - newser.com
Jefferies Maintains PTC Therapeutics (PTCT) Buy Recommendation - Nasdaq
Huntington’s Disease | Clinical Landscape, Key Companies, Therapeutic Assessment, Treatment Algorithms, and Pipeline Insights – featuring leading players such as Hoffmann-La Roche, PTC Therapeutics, A - Barchart.com
PD-1 and PD-L1 Inhibitors Clinical Landscape, Key Companies, Therapeutic Evaluation, Treatment Approaches, and Pipeline Insights | Hoffmann-La Roche, PTC Therapeutics, Annexon, Alnylam Pharmaceuticals - Barchart.com
Bevacizumab: Clinical Overview, Key Companies, Therapeutic Insights, Treatment Strategies, and Pipeline Analysis | Hoffmann-La Roche, PTC Therapeutics, Annexon, Alnylam Pharmaceuticals, Neuvivo, BPG B - Barchart.com
Published on: 2025-10-28 14:58:18 - fcp.pa.gov.br
Bank of America Securities Lifts PT on PTC Therapeutics (PTCT) to $87 From $76 - Insider Monkey
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - Yahoo Finance
Published on: 2025-10-28 05:32:46 - newser.com
24,679 Shares in PTC Therapeutics, Inc. $PTCT Acquired by Convergence Investment Partners LLC - MarketBeat
Ptc Therapeutics Inc Stock (PTCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):